{"id":38434,"date":"2026-04-20T08:32:49","date_gmt":"2026-04-20T06:32:49","guid":{"rendered":"https:\/\/ggba.swiss\/onward-medical-raises-eur-40-million-to-extend-arc-therapy-commercialization\/"},"modified":"2026-04-20T08:35:45","modified_gmt":"2026-04-20T06:35:45","slug":"onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/","title":{"rendered":"ONWARD Medical l\u00e8ve EUR 40 millions pour acc\u00e9l\u00e9rer la commercialisation de sa th\u00e9rapie ARC"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.onwd.com\">ONWARD Medical<\/a> a lev\u00e9 EUR 40,6 millions de produits bruts via un placement acc\u00e9l\u00e9r\u00e9 r\u00e9alis\u00e9 sous forme de placement priv\u00e9 aupr\u00e8s d&rsquo;investisseurs institutionnels. La transaction comprend un investissement de EUR 25 millions d&rsquo;EQT Life Sciences et prolonge la visibilit\u00e9 financi\u00e8re de la soci\u00e9t\u00e9 jusqu&rsquo;au premier trimestre 2028. Cette lev\u00e9e fait suite \u00e0 une <a href=\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-plus-de-eur-50-millions-pour-faire-progresser-ses-therapies-de-la-moelle-epiniere\/\">augmentation de capital de EUR 50,85 millions r\u00e9alis\u00e9e en 2025<\/a>, men\u00e9e par Ottobock et soutenue par Invus et l&rsquo;ASR Global Impact Equity Fund.<\/p>\n\n\n\n<p>ONWARD d\u00e9veloppe des th\u00e9rapies en neurotechnologie con\u00e7ues pour restaurer la mobilit\u00e9 et l&rsquo;autonomie des personnes vivant avec des l\u00e9sions m\u00e9dullaires et d&rsquo;autres troubles du mouvement. Son syst\u00e8me ARC-EX, une plateforme non invasive autoris\u00e9e \u00e0 la commercialisation aux \u00c9tats-Unis et en Europe, est en cours de d\u00e9ploiement sur les march\u00e9s internationaux. En parall\u00e8le, la soci\u00e9t\u00e9 fait progresser son syst\u00e8me implantable ARC-IM en cours d&rsquo;investigation, qui cible des besoins non satisfaits incluant l&rsquo;instabilit\u00e9 de la pression art\u00e9rielle cons\u00e9cutive \u00e0 une l\u00e9sion m\u00e9dullaire, et est explor\u00e9 en combinaison avec des technologies d&rsquo;interface cerveau-ordinateur et l&rsquo;intelligence artificielle pour permettre des mouvements pilot\u00e9s par la pens\u00e9e.<\/p>\n\n\n\n<p>Les nouveaux capitaux financeront le d\u00e9veloppement de produits, les \u00e9tudes cliniques et les travaux r\u00e9glementaires relatifs \u00e0 l&rsquo;ARC-IM, tout en soutenant l&rsquo;expansion des activit\u00e9s commerciales de l&rsquo;ARC-EX aux \u00c9tats-Unis, en Europe et sur des march\u00e9s internationaux s\u00e9lectionn\u00e9s. ONWARD est alumni de Venture Kick, Venture Leaders et du Top 100 Swiss Startups, avec un Centre des sciences et de l&rsquo;ing\u00e9nierie \u00e0 Lausanne, o\u00f9 la recherche fondatrice derri\u00e8re la th\u00e9rapie ARC a \u00e9t\u00e9 d\u00e9velopp\u00e9e \u00e0 l&rsquo;EPFL et au CHUV.<\/p>\n\n\n\n<p>Pour un regard approfondi sur la science derri\u00e8re la technologie d&rsquo;ONWARD, \u00e9coutez notre \u00e9pisode du podcast <a href=\"https:\/\/open.spotify.com\/show\/3oEHA4iaJSBZ5Qu7saxrqC\">Getting Serious avec Gr\u00e9goire Courtine et Jocelyne Bloch<\/a>, les chercheurs de l&rsquo;EPFL et du CHUV dont les travaux pionniers sur la stimulation m\u00e9dullaire ont pos\u00e9 les bases scientifiques des th\u00e9rapies d&rsquo;ONWARD, et qui ont d\u00e9montr\u00e9 pour la premi\u00e8re fois qu&rsquo;un homme paralys\u00e9 pouvait \u00e0 nouveau marcher sur les rives du lac L\u00e9man.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"The Swiss Research That Made a Paralyzed Man Walk Again (with Jocelyne Bloch and Gr\u00e9goire Courtine)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/8rBEeFnRX5o?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d&rsquo;EQT Life Sciences, prolongeant la visibilit\u00e9 financi\u00e8re de la soci\u00e9t\u00e9 jusqu&rsquo;au premier trimestre 2028.<\/p>\n","protected":false},"author":6,"featured_media":38431,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1188,1181,1239,1141,1142],"class_list":["post-38434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-healthcare-fr-2","tag-medical-devices-fr","tag-neuroscience-fr-2","tag-personalized-medicine-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ONWARD Medical l\u00e8ve EUR 40 millions | GGBa<\/title>\n<meta name=\"description\" content=\"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d&#039;EQT Life Sciences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ONWARD Medical l\u00e8ve EUR 40 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d&#039;EQT Life Sciences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T06:32:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T06:35:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ONWARD Medical l\u00e8ve EUR 40 millions pour acc\u00e9l\u00e9rer la commercialisation de sa th\u00e9rapie ARC\",\"datePublished\":\"2026-04-20T06:32:49+00:00\",\"dateModified\":\"2026-04-20T06:35:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\"},\"wordCount\":399,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Medical Devices\",\"Neuroscience\",\"Personalized Medicine\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\",\"name\":\"ONWARD Medical l\u00e8ve EUR 40 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg\",\"datePublished\":\"2026-04-20T06:32:49+00:00\",\"dateModified\":\"2026-04-20T06:35:45+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d'EQT Life Sciences.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"L'\u00e9quipe d'ONWARD Medical d\u00e9veloppe les syst\u00e8mes de th\u00e9rapie ARC, qui d\u00e9livrent une stimulation \u00e9lectrique cibl\u00e9e de la moelle \u00e9pini\u00e8re pour restaurer la mobilit\u00e9, la fonction et l'autonomie des personnes vivant avec des l\u00e9sions m\u00e9dullaires. | \u00a9 ONWARD Medical\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ONWARD Medical l\u00e8ve EUR 40 millions pour acc\u00e9l\u00e9rer la commercialisation de sa th\u00e9rapie ARC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ONWARD Medical l\u00e8ve EUR 40 millions | GGBa","description":"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d'EQT Life Sciences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/","og_locale":"fr_FR","og_type":"article","og_title":"ONWARD Medical l\u00e8ve EUR 40 millions | GGBa","og_description":"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d'EQT Life Sciences.","og_url":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-04-20T06:32:49+00:00","article_modified_time":"2026-04-20T06:35:45+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ONWARD Medical l\u00e8ve EUR 40 millions pour acc\u00e9l\u00e9rer la commercialisation de sa th\u00e9rapie ARC","datePublished":"2026-04-20T06:32:49+00:00","dateModified":"2026-04-20T06:35:45+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/"},"wordCount":399,"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg","keywords":["Financing","Healthcare","Medical Devices","Neuroscience","Personalized Medicine","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/","url":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/","name":"ONWARD Medical l\u00e8ve EUR 40 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg","datePublished":"2026-04-20T06:32:49+00:00","dateModified":"2026-04-20T06:35:45+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ONWARD Medical a obtenu EUR 40,6 millions via un placement acc\u00e9l\u00e9r\u00e9 men\u00e9 par un investissement de EUR 25 millions d'EQT Life Sciences.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/Onward-Team-1180x811-1.jpeg","width":1180,"height":811,"caption":"L'\u00e9quipe d'ONWARD Medical d\u00e9veloppe les syst\u00e8mes de th\u00e9rapie ARC, qui d\u00e9livrent une stimulation \u00e9lectrique cibl\u00e9e de la moelle \u00e9pini\u00e8re pour restaurer la mobilit\u00e9, la fonction et l'autonomie des personnes vivant avec des l\u00e9sions m\u00e9dullaires. | \u00a9 ONWARD Medical"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/onward-medical-leve-eur-40-millions-pour-accelerer-la-commercialisation-de-sa-therapie-arc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ONWARD Medical l\u00e8ve EUR 40 millions pour acc\u00e9l\u00e9rer la commercialisation de sa th\u00e9rapie ARC"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=38434"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38434\/revisions"}],"predecessor-version":[{"id":38436,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38434\/revisions\/38436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/38431"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=38434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=38434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=38434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}